Presentation Title: Mesoporous silica nanoparticle: From tissue regeneration to a good nanocarrier
Prof. Maria Vallet-Regi presented this talk in the webinar on Nanomedicine, Nanomaterials and Nanotechnology organized by Vebleo
Affiliation:
- Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria, Hospital 12 de Octubre i+12, Plaza Ramón y Cajal s/n, Madrid, 28040, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
Biography
Professor Maria Vallet-Regi is a Spanish chemist, scientist and Professor at Universidad Complutense de Madrid, Spain. She is recognized as a pioneer in the field of ceramic materials applied to medicine.
Prof. Maria Vallet-Regi was the pioneer who suggested introducing drugs into the pores of mesoporous silica materials, which inspired thousands of publications worldwide involving mesoporous silica nanoparticles for drug delivery.
She is a Highly Cited Researcher 2018 (Clarivate Analytics). Her publications have been cited over 46.000 times and her h-index is 101. Prof. Maria Vallet-Regi has been awarded many important International prizes. She has recently obtained an ERC Advanced Grant entitled “Polyvalent mesoporous nanosystem for bone diseases.
Abstract
Research on bioceramics has evolved from the use of inert materials for mere substitution of living tissues towards the development of third generation bioceramics aimed at inducing bone tissue regeneration. Mesoporous silica nanoparticles have already proven to be adequate nanocarriers for various chemical and biological species.
For instance, they are valuable tools when carrying antitumor agents selectively to a tumor tissue, and releasing them there thanks to the application of an external stimulus. We use the term smart because those nanocarriers are able to release the drugs when and where they are needed.
The surface of our nanosystems can be decorated with molecules able to recognize specifically tumor cells and to trigger the penetration of nanocarriers into them.
The main advantage of developing selective nanocarriers able to accumulate only in tumor tissues are: increased selectivity of the therapy, which allows reducing the cytotoxic dosage; higher control over the administered doses; and the reduction of side effects, because the drugs will not be distributed throughout the whole body.
Taking into account that most anticancer drugs are cytotoxic, their release must take place only inside tumor cells.
Graphical Abstract
Different scales of mesoporous silica materials and schematic layout of potential modifications to its inner and outer surfaces of mesoporous silica nanoparticles.
This talk was delivered in the webinar organized by Vebleo